DDInter1771 DDInter1376
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Teriflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Teriflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melatonin
Teriflunomide {u} may lead to a major life threatening interaction when taken with {v} Mephenytoin
Teriflunomide {u} may lead to a major life threatening interaction when taken with {v} Asparaginase Erwinia chrysanthemi
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Melatonin
Teriflunomide may lead to a major life threatening interaction when taken with Mephenytoin
Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi